Herantis Pharma to Host an R&D Update Webinar on October 26, 2021
Herantis Pharma Plc, Company release, 20 October 2021 at 9:30 EEST Herantis Pharma Plc (“Herantis or the Company”), focusing on disease modifying therapies for debilitating neurodegenerative diseases will October 26[th], 2021 host an R&D Update Webinar. Herantis’ CEO Dr. Craig Cook and CSO Dr. Henri Huttunen will share progress in advancing Herantis’ HER-096 and rhCDNF programs. The R&D update will cover: · Information about Herantis’ novel biomarker focused development program · Data on efficient blood brain barrier (BBB) crossing · Results from pre-clinical experiments